Distamycin A hydrochloride
Distamycin A hydrochloride (NSC-82150 hydrochloride) is an oligopeptide pyrrole antibiotic. Distamycin A hydrochloride inhibits DNA-dependent DNA polymerase and inhibits DNA-dependent RNA polymerase by blocking sigma-dependent initiation complex formation. Distamycin A hydrochloride exhibits antiviral activity against DNA viruses, antibacterial activity against Gram-positive bacteria and fungi, and antiproliferative activity against leukemia cells. Distamycin A hydrochloride can be used in research on viral infections, leukemia, and cancer.
For research use only. We do not sell to patients.
- CAS No.: 6576-51-8
- Formula: C22H28ClN9O4
- Molecular Weight:517.97
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Distamycin A hydrochloride inhibits DNA-dependent DNA synthesis using natural herring sperm DNA as a template[1].
Distamycin A hydrochloride shows similar effectiveness against SV40 DNA and calf thymus DNA in RNA polymerase assays[1].
Distamycin A (20-80 µM; 15 min) hydrochloride selectively inhibits the binding of transcription factors SRF and MEF2 to their respective A/T-rich elements in nuclear extracts of C2C12 myotubes, without affecting the binding of Sp1 or MyoD[2].
Distamycin A (20-40 µg/mL; 3 days) hydrochloride reversibly inhibits the morphological differentiation of C2 myoblasts without significantly affecting cell growth[2].
Distamycin A (20-40 µg/mL; 7 days) hydrochloride enhances adipocyte differentiation by approximately 4-fold in pluripotent TA1 cells while inhibiting myogenic differentiation by 85%[2].
Distamycin A (40 µg/mL) hydrochloride strongly downregulates endogenous muscle-specific gene transcripts (cardiac α-actin, skeletal α-actin, myosin heavy chain, and myoD1) in differentiating C2 cells without affecting non-muscle gene transcripts[2].
Distamycin A (40 µg/mL; 48 h) hydrochloride inhibits human cardiac α-actin promoter activity by 73% and human skeletal muscle α-actin promoter activity by 35% in C2 cells, while it does not inhibit the β-actin or c-fos promoter[2].
Distamycin A (20-80 µg/mL; 48 h) hydrochloride inhibits the human cardiac α-actin promoter in a dose-dependent manner in CV-1 cells, even upon ectopic expression of myoD, indicating that this inhibition is not due to suppression of myoD expression[2].
Distamycin A (40 µg/mL; 48 h) hydrochloride selectively inhibits MEF2-dependent promoter activity by 82% in CV-1 cells, while it does not inhibit MyoD-dependent promoter activity[2].
Distamycin A (1.2 × 10-6 M; 2-5 min) hydrochloride mainly inhibits RNA chain initiation by E. coli RNA polymerase on T4-DNA; when the Distamycin/DNA ratio is 1:10, [14C]UMP incorporation decreases to 2.5% of the control, whereas preincubation renders the system resistant[1].
Distamycin A (6-20 μM) hydrochloride inhibits DNA-dependent DNA polymerase (from Ehrlich ascites tumor cells) at 6 μM by binding to the DNA template, and inhibits RNA polymerase (from Escherichia coli) with a 50% inhibitory concentration of 10-20 μM[4].
Distamycin A (20 h) hydrochloride induces resistance in Bacillus subtilis strains PB 1689, PB 1717, and PB 1718, with a minimum inhibitory concentration of 200 μg/mL, compared to 20 μg/mL for the parental strain PB 202[7].
Distamycin A (50 μg/mL) hydrochloride induces a dst-3 mutation in Bacillus subtilis PB 1689, conferring resistance to growth inhibition, with the mutant being affected only at doses above 100 μg/mL compared to 50 μg/mL for the parental strain PB 202[7].
Distamycin A (48 h) hydrochloride exhibits low cytotoxic activity against L1210 mouse leukemia cells with an IC50 of 10069 nM[6].
Distamycin A (48 h) hydrochloride shows cross-resistance in both Doxorubicin (HY-15142A)- and Tallimustine (HY-105270)-resistant L1210 leukemia cell lines, with IC50 values of 459 μM and 142 μM, respectively[6].
Distamycin A (2-3 μg/mL) hydrochloride protects Bacillus subtilis cells from SPP1 phage-induced lysis, possibly through osmotic stabilization of the cell envelope, without affecting phage infection and proliferation[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:C2
-
Concentration:20 µg/mL; 40 µg/mL
-
Incubation Time:3 days; 48 h (reversibility)
-
Result:Eliminated morphological differentiation at 20-40 µg/mL.
Displayed less than 1% of cells fused into myotubes at 40 µg/mL compared to greater than 95% fusion in control cells.
Showed minimal effect upon C2 myoblast growth at 40 µg/mL or lower.
Completely reversed inhibition of cellular differentiation following removal and additional 48 h culture.
-
Cell Line:TA1
-
Concentration:20-40 µg/mL
-
Incubation Time:7 days
-
Result:Increased lipid producing cells approximately 4-fold at 40 µg/mL.
Repressed myogenic differentiation by 85% at 40 µg/mL.
Chemical Information
-
CAS No. 6576-51-8
-
Molecular Weight 517.97
-
Formula C22H28ClN9O4
-
SMILES
O=CNC1=CN(C)C(C(NC2=CN(C)C(C(NC3=CN(C)C(C(NCCC(N)=N)=O)=C3)=O)=C2)=O)=C1.Cl
-
Synonyms
NSC-82150 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
[5]. Beria I, et al. Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners. Journal of medicinal chemistry. 2004 May 06;47(10):2611-23. [Content Brief]
[6]. Baraldi PG, et al. Synthesis and antitumor activity of new benzoheterocyclic derivatives of distamycin A. Journal of medicinal chemistry. 2000 Jul 13;43(14):2675-84. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Distamycin A
- 6576-51-8
- NSC-82150
- NSC82150
- NSC 82150
- Antibiotic
- Bacterial
- Fungal
- Nucleoside Antimetabolite/Analog
- DNA/RNA Synthesis
- Gram-positive bacteria
- E. coli RNA polymerase
- DNA-dependent RNA polymerase
- double-stranded B-DNA
- Rauscher murine leukemia virus reverse transcriptase
- leukemia cells
- A-T-rich regions
- DNA-dependent DNA polymerase
- L1210 murine leukemia cells
- Ehrlich ascites tumor cells
- Inhibitor
- inhibitor
- inhibit